Articles by Brian
-
What an Elementary School Drop-off Line Can Teach Us About Product Design
What an Elementary School Drop-off Line Can Teach Us About Product Design
This morning I was chastised for incorrectly approaching the drop-off line at my daughter's school. After she exited…
1 Comment -
Finding Unexpected Mentors
Finding Unexpected Mentors
I've been very fortunate to have great mentors throughout my career - people who were willing to let me succeed or fail…
1 Comment -
What lunch at sweetgreen taught me about the importance of teamwork
What lunch at sweetgreen taught me about the importance of teamwork
Teamwork is critical in business. It's kinda inarguable at this point right? I doubt that anyone reading this post…
1 Comment
Activity
1K followers
-
Brian Dranka shared thisA pair of papers out in NEJM AI identified a modest but promising value for AI scribes in physician/patient interactions. Both papers report the findings of randomized controlled trials primarily evaluating physician burnout. What I find most interesting about this is the benefit in perceived exhaustion, which (though I'm not a physician) I can certainly empathize with. Yes, there's a modest time savings per patient visit. But it's clear to me that the real value in these systems will be down to improving quality of interaction rather than decreasing the quantity (time) of interaction. Editorial on the papers --> https://lnkd.in/e9ivrJgv #AIinHealthcare
-
Brian Dranka reposted thisWe are so proud to work with Eric Brown, Geordie Stewart, PhD MBA and Timsy Bhando, Ph.D. at Kapoose Creek Bio. It's been amazingly stimulating intellectually, sorting through data and trying to understand the mechanism better. Thank you so much for including us in your journey.Brian Dranka reposted thisWe’re thrilled to announce that Kapoose Creek Bio has partnered with Terrain Life Science, a leader in clinical-grade spatial proteomics, to further advance the development of our lead therapeutic candidate, KCB-100 – a novel small molecule currently in development for treating depression. This collaboration brings together Terrain’s advanced spatial biology platform and our own AI-powered unEarthRx technology to accelerate the discovery and development of first-in-class therapies from nature. By leveraging Terrain’s advanced proteomics, we will gain unprecedented insights into the mechanism of action and efficacy of KCB-100. This partnership exemplifies our commitment to combining breakthrough science and technology to uncover life-changing therapies from nature, faster than ever before. To read more: https://lnkd.in/gxAmWKpv #Biotech #DrugDiscovery #AI #Neuroscience #Partnership #Innovation #KapooseCreekBio #Terrain
-
Brian Dranka shared thisVery excited to partner with Chris Walsh, David Chang, John Le Quesne, and Ke Yuan from TileBio. Our team is moving fast at Terrain Life Science - ping me if you want to learn more about how we view the future of precision medicine!Brian Dranka shared thisToday, Terrain Life Science and TileBio announce a strategic partnership, uniting two cutting-edge platforms to advance the future of AI-powered precision medicine. Together, we're taking a significant step toward a future where every patient can receive the right drug at the right time. Read the full announcement on our website here --> https://lnkd.in/e8mWEkuK #PrecisionMedicine #Partnership #AIforHealthcare
-
Brian Dranka shared thisI believe that the future of medicine is 𝗱𝗮𝘁𝗮-𝗳𝗶𝗿𝘀𝘁 rather than indication or target-first. For decades drug discovery has been a target-first endeavor. In the future we'll measure drug targets much more thoroughly and get closer to the right drug for the right patient at the right time. You might even call it personalized medicine! The data generated in this future state will also power new approaches to drug discovery and development. I wrote lots more on that topic for our blog --> https://lnkd.in/e7kRzRZA #spatialproteomics #drugdiscoveryWhy AI-Ready Spatial Data is the New Gold Standard in Drug DiscoveryWhy AI-Ready Spatial Data is the New Gold Standard in Drug Discovery
-
Brian Dranka posted thisVery happy to announce that we've entered into a strategic partnership with Splice Histology, Inc. The collaboration is focused on a simple but powerful goal: accelerating analysis of tissue samples with our approach to spatial proteomics. More, varied samples provide more data which improves our models. A huge thank you to Tom Schofield, Bruce Mageshwar and the entire team at Splice. We're excited about the innovative work we can accomplish together to advance the frontiers of precision medicine. Read the full announcement on our website here --> https://lnkd.in/e7Naw9yK #Partnership #SpatialProteomics #PrecisionMedicine
-
Brian Dranka reposted thisBrian Dranka reposted thisNEW: There's a prisoner's dilemma-like problem for AI in pharma R&D. If drugmakers collaborated and shared data, it'd be far easier to tap the full power of AI. But they'd also risk ceding a competitive edge. Large drugmakers have kept their data locked up and siloed, but a new Eli Lilly and Company initiative tries to change that. TuneLab debuted Tuesday, offering biotech startups free access to a suite of Lilly's own AI/ML models for small molecule ADMET property prediction and antibody developability. Early partners include Firefly Bio, Superluminal Medicines Inc., and Circle Pharma, Inc. Each participant will contribute their own training data to further improve the models, via a federated learning setup that protects the raw data while helping build better, more generalizable models. My latest for Endpoints News here, talking with Lilly's Aliza Apple, Nisha Nanda, insitro CEO Daphne Koller, and Firefly's CEO Scott Hirsch: https://lnkd.in/ebJcAq83In first-of-its-kind setup, Lilly offers startups free access to its AI models in exchange for dataIn first-of-its-kind setup, Lilly offers startups free access to its AI models in exchange for data
-
Brian Dranka posted thisI spent yesterday afternoon with leaders from Sanofi, Amgen, J&J, and others discussing use cases for AI and I left with one big takeaway: They're laser-focused on business value, not hype! It was honestly refreshing. Maybe you're not surprised by this, but it's a good reminder to step back, turn down the news/noise, and remember what actually matters: delivering value for our clients, patients, and stakeholders. Hearing their intense focus on doing the right thing and building evidence for their internal AI initiatives was inspiring, as were the keynotes. With new AI models and press releases dropping daily, the hype in healthcare and life sciences is real. Staying data-driven is more important than ever. #AIforPharma #StepAwayfromtheHype
-
Brian Dranka shared thisJust sending out this reminder to everyone that there's great science and great product development happening out there! Thanks Arthur Tzianabos for the perspective. https://lnkd.in/eUy2fA6P“We Got This”: Don’t Let Negativity Become a Self-fulfilling Prophecy - LifeSciVC“We Got This”: Don’t Let Negativity Become a Self-fulfilling Prophecy - LifeSciVC
Brian Dranka commented on a post
1mo
And every one of those relationships has the potential to make our break your product!
Brian Dranka replied to a comment
2mo
Rafael Rosengarten Maybe this is the first time a classic product-led growth approach (like Dropbox or Slack) will be successful in healthcare. Curious if anyone knows another example??
-
Brian Dranka liked thisCome join! It'll be a great conversation.Brian Dranka liked thisEveryone's making AI investment calls right now and pretending they're confident about it 😅 This panel is four CPOs being honest about the ones they got wrong. Quick one for any senior product leaders in the Boston area 👋 I'm on the team putting together CPO Summit Boston (Aug 20), and this panel might be my favorite one on the agenda: build vs. buy vs. embed, and how CPOs are actually making AI investment decisions right now. 🎤 Errol Apostolopoulos, CPO, CPO Copilot 🎤 Silvia Tower, CPO, Jaia Robotics 🎤 Jonathan Sheffi, VP of Strategy & Product Excellence, Clarivate 🎤 Ashish Bhatia, Product Leader, Audible No pitch decks. No theory. Just what they got right, what they'd change, and where it went sideways. ⏳ 6 weeks away, 100 seats, invite-only. If you're a senior product leader in the Boston area, I'd love to get you in the room 👉 https://lnkd.in/ea9arqvu
-
Brian Dranka liked thisBrian Dranka liked thisA wake up call for Biopharma. They did it to Figma, they did it to Cursor, now they are coming after you. https://lnkd.in/gFBE5v4MThe Foundation Model Trap: A Wake-Up Call For BiopharmaThe Foundation Model Trap: A Wake-Up Call For Biopharma
-
Brian Dranka liked thisBrian Dranka liked thisA proud moment for the Candel Therapeutics team. Seeing congratulations to Mark Sims displayed on the Nasdaq Tower in Times Square is a reminder that building a great company starts with building a great team. Mark brings deep commercial expertise and a passion for improving the lives of patients. As we advance toward commercialization while expanding our late-stage pipeline, we're excited about what lies ahead. Welcome aboard, Mark. The journey is just getting started. #Leadership #Biotech #Oncology #Commercialization #TeamCandel #Nasdaq
-
Brian Dranka liked thisBrian Dranka liked thisDetecting a mitochondrial signal is only the beginning. Yvonne Will, PhD, ATS Fellow shared this publication last week, and I wanted to add my own perspective and thanks. I’m very pleased that our article in Expert Opinion on Drug Discovery, “From mitochondrial signal to discovery decision: a reserve–demand framework for translational risk assessment,” is now published. Thank you, Yvonne, for the opportunity to work together on this. I appreciated the collaboration and the chance to think carefully about a problem that has been central to mitochondrial safety assessment for many years. Mitochondrial assays can generate highly informative data, but the harder question is how a signal should be interpreted in relation to biological reserve, functional demand, exposure relevance, progression over time, and translational context. That is the purpose of the reserve–demand framework: to help move from isolated assay findings toward more structured, decision-relevant interpretation. This paper also reflects a broader issue across life-science R&D: generating complex biological data is not the same as generating decision-ready evidence. Measurements create the most value when the biology, assay system, data outputs, interpretation, claims, and intended decision remain aligned. Thank you as well to David Grech, the editorial team, and the reviewers for their constructive input and for helping improve and strengthen the final article. The complete article is available through the Taylor & Francis ePrint link below: https://lnkd.in/gJ-Ew-96 #DrugDiscovery #Mitochondria #Toxicology #DrugSafety #TranslationalScience
-
Brian Dranka liked thisBrian Dranka liked thisThis morning someone asked me "are you scared by the Anthropic claude for science" Me: "of course not - super excited by it the launch was amazing" Him "can Owkin compete?" Me" of course. The harness we have (data skills tools wet lab and real world validation) is not only based on performance of the models- it is based on trust with hospitals and real world patient training and validation with actual solution/ (molecules or diagnosis or care decisions). Biology is great but it needs to be connected to hospitals. R and D to care" Him "how platform can be benchmarked" Me "it is easy. In two years Let's just measure the n. N being the number of patients that will be cured or treated with solutions when nothing was available" It is THAT simple!
-
Brian Dranka liked thisBrian Dranka liked thisToday we launched Claude Science, an AI workbench for scientific research, in public beta. Research tooling is brutally fragmented. A single analysis can mean a dozen databases, Jupyter, R, a cluster terminal, and a ton of file formats. Claude Science pulls all of that into one place. It runs analyses, searches the literature, renders protein structures natively, and manages compute on your lab's own infrastructure. Some early results: a neuroscientist at the Allen Institute can now produce 100+ page, fully cited literature reviews that used to take his team two years. An epidemiologist at UCSF is running germline analyses in a tenth of the time. Manifold Bio used it to nominate targets for their latest experiments. Part of why I'm at Anthropic is the belief that AI can compress decades of scientific progress into a few years. This is a step in that direction. It's a beta, so try it, tell us where it breaks! claude.com/science https://lnkd.in/eKnMNSf3
-
Brian Dranka reacted on thisBrian Dranka reacted on thisMy physician wife casually drops: “Oh I was playing with Posit to create some R-code, and with that I found anomalies in our data that were super int’g. Claude helped me clean up the charts and plots to send to the team so they could also review.” AI gives you superpowers!
-
Brian Dranka liked thisBrian Dranka liked thissome thoughts on Claude Science, and Anthropic's ambitions in drug development: 1. i doubt they are developing their own therapeutic pipeline and will become a drug maker. in bio, the key bottleneck is evals and verification, and this is best done by dogfooding their own tools and workflows. in software, ground truth compiles cheaply/instantly. opposite is true in bio. claude code started as an internal tool before it was a product; i expect most of Anthropic's future bio tools to follow the same path. 2. focusing on “neglected diseases” may reflect their PBC status, but it also makes the platform less threatening to pharma/biotech customers. customers are more likely to build on Claude if they don’t think Anthropic will compete with them. 3. one interesting question is what will happen to any assets/molecules they develop internally. i doubt they push them into clinic, but my low-confidence prediction is that they will explore an Isomorphic-style spin out in 12-18 months. 4. the ecosystem / integration strategy is exciting, but creates a platform gatekeeper risk. will be interesting to see if this plays out similarly to the EHR Epic and AI scribes: scribe companies gained distribution by integrating into the EHR, but Epic is now building native scribe functionality, and those partners now risk being blocked or deprioritized. if Anthropic becomes the workflow layer for AI-bio, similar dynamics could emerge. 5. the core bet seems to be that value in AI-bio accrues at the orchestration / workflow layer, not the model/weights. that is a very different bet from other labs like DeepMind (AlphaFold, AlphaMissense, etc).
-
Brian Dranka liked thisBrian Dranka liked thisI'm hiring someone to reimagine how we think about product support. This is a build role where you'll define the function, not inherit one. AI-native model, high autonomy, real organizational mandate. If you've built a support function before and know how to operate at the intersection of product, engineering, and commercial teams, shoot me a message. https://lnkd.in/g2EpVUe3
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
University of Alabama at Birmingham
-
-
Activities and Societies: Molecular and Cellular Pathology Graduate Program Presiding Officer, Graduate Student Association Senator, Center for Free Radical Biology Trainee
Graduate Student in the lab of Dr. Victor Darley-Usmar from 2005-2009. I studied the influence of oxidative stressors on the bioenergetics of intact cells.
Most Outstanding Graduate Student - Department of Pathology 2009
Dissertation entitled "Mitochondrial Bioenergetics and Cellular Stress" 2009 -
-
Publications
-
Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation.
Journal of Neurochemistry
In vitro and in vivo models of Parkinson's disease (PD) suggest that increased oxidant production leads to mitochondrial dysfunction in dopaminergic neurons and subsequent cell death. However, it remains unclear if cell death in these models is caused by inhibition of mitochondrial function or oxidant production. The objective of this study was to determine the relationship between mitochondrial dysfunction and oxidant production in response to multiple PD neurotoxicant mimetics. MPP(+) caused…
In vitro and in vivo models of Parkinson's disease (PD) suggest that increased oxidant production leads to mitochondrial dysfunction in dopaminergic neurons and subsequent cell death. However, it remains unclear if cell death in these models is caused by inhibition of mitochondrial function or oxidant production. The objective of this study was to determine the relationship between mitochondrial dysfunction and oxidant production in response to multiple PD neurotoxicant mimetics. MPP(+) caused a dose-dependent decrease in the basal oxygen consumption rate in dopaminergic N27 cells, indicating a loss of mitochondrial function. In parallel, we found that MPP(+) only modestly increased oxidation of hydroethidine as a diagnostic marker of superoxide production in these cells. Similar results were found using rotenone as a mitochondrial inhibitor, or 6-hydroxydopamine (6-OHDA) as a mechanistically distinct PD neurotoxicant, but not with exposure to paraquat. In addition, the extracellular acidification rate, used as a marker of glycolysis, was stimulated to compensate for oxygen consumption rate inhibition after exposure to MPP(+) , rotenone, or 6-OHDA, but not paraquat. Together these data indicate that MPP(+) , rotenone, and 6-OHDA dramatically shift bioenergetic function away from the mitochondria and towards glycolysis in N27 cells.
Other authors -
-
Assessing bioenergetic function in response to oxidative stress by metabolic profiling.
Free Radical Biology and Medicine
This article describes our approach to the study of bioenergetic function in cultured cells. We focus on the consequences of oxidant production using exposure to various toxicants, though the methods are applicable to many other scientific paradigms. The article ends with some best-practices and suggestions for accurate data analysis.
Other authors -
Recommendations received
2 people have recommended Brian
Join now to viewOther similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content